Thoroughbred Therapeutics

Thoroughbred Therapeutics is a biotechnology company focused on the development of targeted therapies for oncology, specifically targeting the EphA2 receptor. The company was founded by Dr. Michael Kinch, who is recognized for his pioneering work in identifying EphA2 as a key driver in cancer progression and metastasis. Thoroughbred Therapeutics utilizes monoclonal antibody technology to develop precision medicines aimed at treating various solid tumors where EphA2 is overexpressed. The company's research emphasizes the potential of EphA2 as both a diagnostic marker and a therapeutic target to improve outcomes for patients with aggressive cancers. By focusing on the unique biology of Eph receptors, Thoroughbred Therapeutics aims to advance a pipeline of novel biologics from discovery through early-stage development.